Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
07 nov. 2023 07h00 HE
|
Mersana Therapeutics, Inc.
Advancing dose escalation portion of Phase 1 clinical trial of XMT-1660, Mersana’s B7-H4 Dolasynthen ADCPreparations underway to resume enrollment in Phase 1 clinical trial of XMT-2056, Mersana’s HER2...
Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023
31 oct. 2023 16h30 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056
31 oct. 2023 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Changes in Leadership
06 sept. 2023 07h00 HE
|
Mersana Therapeutics, Inc.
Anna Protopapas to retire as President and Chief Executive Officer (CEO); will remain a member of the Board of DirectorsMartin Huber, M.D., current member of the Board of Directors, to be named...
Mersana Therapeutics Announces Second Quarter 2023 Financial Results
08 août 2023 08h00 HE
|
Mersana Therapeutics, Inc.
Organization fully focused on product candidates and collaborations based on next-generation ADC platformsCapital resources expected to support current operating plan commitments into 2026 CAMBRIDGE,...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 août 2023 16h05 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization
27 juil. 2023 07h06 HE
|
Mersana Therapeutics, Inc.
UPLIFT clinical trial did not meet its primary endpoint Company realigns focus and significantly reduces expenses to extend cash runway into 2026Conference call today at 8:00 a.m. ET CAMBRIDGE,...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 juil. 2023 16h05 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials
15 juin 2023 07h30 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 juin 2023 16h05 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...